ArticleThe Journal of physiology2026
Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats.
Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Central leptin resistance precedes obesity and drives early endocrine dysfunction.The Journal of physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Brain leptin signalling plays a central role in the regulation of energy balance and glucose homeostasis, yet its contribution to early metabolic dysfunction preceding overt obesity remains uncertain. In the present study, we examined the metabolic consequences of sustained attenuation of central leptin receptor signalling in lean rats. Adult animals received chronic i.c.v. infusion of a rat-specific leptin receptor antagonist (SLA) or vehicle for 21 days. SLA administration increased food intake with modest gains in body weight and visceral adiposity at the same time as maintaining normoleptinemia, and induced hepatic and pancreatic lipid accumulation, hyperinsulinemia, impaired glucose tolerance and hyperglucagonemia. These alterations were accompanied by hepatic glucagon resistance, as indicated by attenuated gluconeogenic gene induction and reduced CREB phosphorylation following in vivo glucagon stimulation. SLA-infused rats also exhibited elevated circulating total and branched-chain amino acids, reduced hepatic branched-chain α-ketoacid dehydrogenase activity and increased fibroblast growth factor 21 levels, consistent with disrupted glucagon-amino acid signalling. Together, these findings indicate that impaired central leptin signalling induces co-ordinated endocrine and metabolic disturbances in the absence of obesity, supporting a role for altered central neuroendocrine regulation in the early development of metabolic dysfunction. KEY POINTS: Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats. Central leptin disruption leads to hyperglucagonemia, hepatic glucagon resistance and altered amino acid metabolism. Elevated fibroblast growth factor 21 levels and impaired branched-chain amino acid catabolism reflect early liver-α-cell axis dysregulation. This model provides insight into neuroendocrine drivers of non-obese prediabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.